IJPMBS 2024 Vol.13(4): 136-143
doi: 10.18178/ijpmbs.13.4.136-143
doi: 10.18178/ijpmbs.13.4.136-143
Research Progress of NK Cell-Based Immunotherapy for Tumors
Yiming Chen
Jurong Country Garden School, Nanjing, Jiangsu, China
Email: 2042558527@qq.com
Email: 2042558527@qq.com
Manuscript received September 6, 2024; revised September 30, 2024; accepted October 8, 2024; published December 25, 2024.
Abstract—Nowadays, immunotherapy plays an important role in the comprehensive treatment of tumors. As an immune cell, Natural Killer (NK) cells have many advantages in tumor immunotherapy and will become a potential tumor immunotherapy. This dissertation will investigate three types of NK cell-based immunotherapies, namely NK cell infusion therapy, immune checkpoint blockade therapy, and CAR-NK therapy. The potential of immunotherapy based on NK cells has been demonstrated in various clinical trial cases. At the same time, it shows that there are still some key questions about NK cells, such as how to prepare NK cells, the selection of NK cell donors, and how to improve the function of NK cells. This article reviews the research progress of NK cell-based immunotherapy, which is expected to provide new ideas for the clinical treatment of tumors.
Keywords—CAR-NK, immune checkpoint blockade, NK cell, tumor immunotherapy
Cite: Yiming Chen, "Research Progress of NK Cell-Based Immunotherapy for Tumors," International Journal of Pharma Medicine and Biological Sciences, Vol. 13, No. 4, pp. 136-143, 2024.
Copyright © 2024 by the authors. This is an open access article distributed under the Creative Commons Attribution License (CC BY-NC-ND 4.0), which permits use, distribution and reproduction in any medium, provided that the article is properly cited, the use is non-commercial and no modifications or adaptations are made.